IGF-1 LR3 Overview, Dosing & Safety | Peptide Database

IGF-1 LR3 (Long R3 IGF-1)

Modified Growth Factor Analog | Muscle Growth

Community Research

Join others researching IGF-1 LR3 — share findings, ask questions, and learn from real experiences

IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has never been approved for human use. The N-terminal extension and R3 substitution reduce binding protein interaction, maintaining elevated free circulating levels with ~3x greater potency than native IGF-1.

Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.

Molecular Data

Research Indications

15-20% lean mass gains in 4 weeks through satellite cell activation (rat studies).

Cancer cachexia rats maintained 30% more muscle versus placebo.

Creates new muscle fibers via satellite cell differentiation.

Accelerated wound healing in animal models.

Enhanced connective tissue repair.

Directs nutrients toward muscle tissue.

Enhanced lipolysis through IGF-1 pathway.

Dosing Protocols

Subcutaneous or intramuscular injection. CRITICAL: Consume 30-60g fast carbohydrates immediately after injection to prevent hypoglycemia. Never inject before sleep.

Beginner Protocol

20-30mcg

Once daily post-workout

SubQ/IM

Intermediate

40-60mcg

Once daily

Advanced

80-100mcg

Once or split AM/PM

Women's Protocol

10-20mcg

Reconstitution Instructions

IGF-1 LR3 lyophilized powder

0.6% acetic acid OR bacteriostatic water

Insulin syringes (29-32 gauge)

Alcohol swabs

1 Equilibrate to room temperature (15-30 min)

2 Sanitize rubber stopper with alcohol

3 Calculate concentration (e.g., 1mg in 2mL = 500mcg/mL)

4 Inject diluent slowly along vial wall

5 Gently swirl - never shake vigorously

6 Allow 2-5 minutes for complete dissolution

7 Store immediately at 2-8°C protected from light

8 Acetic acid reconstitution: stable 1 year

9 BAC water reconstitution: use within 7 days

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Hypoglycemia (lasting up to 30 hours) - CRITICAL

Water retention

Joint stiffness

Muscle soreness

Increased pump during workouts

Stop Signs - Discontinue if:

Severe or recurring hypoglycemia despite carbohydrate intake

Unusual growths, lumps, or rapid mole changes

Severe joint pain or carpal tunnel symptoms

Persistent nausea, headaches, or vision changes

Signs of organ enlargement

Extreme fatigue or mental fog

Contraindications

NEVER approved for human use - research chemical only

Cancer history or undiagnosed growths

May cause organ hypertrophy (heart, intestines)

WADA prohibited - causes failed drug tests

Quality Checklist

Good Signs

HPLC purity >95%

Mass spectrometry confirmation

Cold storage maintained (-20°C lyophilized)

Certificate of analysis from reputable source

Warning Signs

Research chemical status - never approved for human use

Zero human clinical trials exist

Species-specific responses vary significantly

Bad Signs

Severe hypoglycemia risk - life-threatening low blood sugar lasting 20-30 hours

Cancer proliferation concern - UK Biobank links elevated IGF-1 to multiple cancers

Black market quality varies - oxidized and degraded forms common

Frequently Asked Questions

Why is IGF-1 LR3 called 'long R3'?

The N-terminal extension and R3 (arginine) substitution reduce binding to IGF binding proteins, allowing the peptide to circulate freely for 20-30 hours instead of being sequestered. This gives it approximately 3x greater potency and systemic presence than native IGF-1.

Can I take IGF-1 LR3 with HGH?

Not recommended. Both are IGF-1 pathway agonists, and combining them creates excessive IGF-1 levels with amplified side effects including severe hypoglycemia, joint pain, organ enlargement risk, and carpal tunnel symptoms.

How long can I safely use IGF-1 LR3?

Maximum recommended cycle is 4-6 weeks with equal off-time. Prolonged use risks receptor desensitization, excessive organ growth, and cumulative hypoglycemia danger. Most users run 4-6 week cycles with 4-6 weeks off between.

What happens if my blood sugar drops dangerously low on IGF-1 LR3?

Severe hypoglycemia from IGF-1 LR3 can last 20-30 hours due to the long half-life. Consume 30-60g fast carbs immediately after injection and keep glucose tablets handy. Never inject before sleep. Consider having glucagon available for emergency hypoglycemia.

References

LR3IGF-I was approximately 2.5-fold more potent than native IGF-1 in reversing dexamethasone-induced catabolism. 7-day treatment showed significant body weight recovery vs 19g loss in controls.

Fetal plasma insulin concentrations decreased 66% with IGF-1 LR3 infusion during hyperglycemic clamp. Insulin secretion suppression was acute and did not persist in isolated islets.

IGF-1 treatment effectively attenuated host muscle protein and lean tissue depletion in a sarcoma model without stimulating tumor growth. Dose-dependent increases in carcass weight and gastrocnemius muscle protein.

Higher circulating IGF-1 associated with increased risks of colorectal, breast, prostate, and thyroid cancers in the UK Biobank prospective cohort of >395,000 participants.

Related Peptides

Complementary healing mechanisms.

Different repair pathway activation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.